The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
Transcript
What are you hoping comes after the Oncology Care Model (OCM)? What learnings from OCM should be in the successor model?
Yeah, I think that, first of all, it remains to be seen if there will be a successor, I hope there will be. I think that the OCM has been very good for patients. I think it's been good for changing the way that oncology is delivered. One of the things about the OCM, that's not talked about as much as cost savings and bending the cost curve is the change in the way care is delivered. And it really drove a lot of good things. I think patients were getting more attention, more coordination of care, more efforts to keep people out of the hospital and the emergency room, better evaluation of data to learn from the program. So, there was a lot of good with the OCM, I thought it was actually a great program and did a lot of good things for practices and, again, for patients.
But it's over, you know, in about 6 months. So, I think that it would be great if Medicare, [Center for Medicare and Medicaid Innovation] looked at another model—one that continues to drive value—and also look at ways to reimburse [and] pay for cancer care in an appropriate way. It's very, very expensive. There is a lot of utilization that’s not always needed. And I think there's still value in trying to explore better ways to pay for what's very expensive care.
Was there something missing from OCM that you would like to see in the successor model?
I think that in a subsequent model, I would continue to support the more comprehensive staff and infrastructure at practices. That is expensive; it's typically not reimbursed. So, to find a way to support that I think would be very important. Otherwise, there's a risk that nutritionist and social workers and community practice really can't be afforded. So, I think that's one thing I would definitely try to keep going in the next model, if you will.
I think that there does need to be continued focus on drugs. When you look at the baseline data for the OCM. The data that was calculated prior to the program beginning—2012 to 2015—drugs took up about 40% of the overall cost per episode. They're now at about 70%. This isn't necessarily a bad thing. There's been a lot of advances in drug therapy, but it's very, very, very expensive and that will be the focus whether you know participants like it or not.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More